Recent advances in gestational trophoblastic disease.
Recent advances have increased our understanding of gestational trophoblastic disease, and epidemiologic studies have demonstrated that there are important differences in risk factors for complete and partial mole. Complete moles are now increasingly being diagnosed in the first trimester, affecting their clinical presentation and pathologic characteristics. While important advances have been made in chemotherapy, it is now recognized that etoposide is associated with a risk of second tumors. Several studies have advanced understanding of the molecular biology of gestational trophoblastic disease, and this is important for the eventual development of new and innovative therapy.
Schorge
J O
JO
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Goldstein
D P
DP
Bernstein
M R
MR
Berkowitz
R S
RS
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D011247:Pregnancy; D011379:Prognosis; D012307:Risk Factors; D014328:Trophoblastic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*
D000970:Antineoplastic Agents; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005047:Etoposide